I. COMMENCED TRADING IN December | ||||||||
Company (Symbol)# |
Date Filed |
Date Comm. |
Shares/Units (M) |
Price |
Shares Out (M)@ |
Lead, Other Underwriters |
Gross (US$M) |
Post-Offering Market Cap (M)% |
INITIAL OFFERINGS | ||||||||
AcelRx Pharmaceuticals Inc. (Redwood City, Calif.; ACRX)1 |
11/12/10 |
2/11 |
8S |
$5 |
19.4 |
Piper Jaffray Cowen & Co. Canaccord Genuity JMP Securities |
$40 |
$97 |
BG Medicine Inc. (Waltham, Mass.; BGMD)2 |
1/29/10 |
2/4 |
5.75S |
$7 |
19.15 |
Lazard Capital Markets Robert W. Baird Cowen & Co. |
$40.25 |
$134.05 |
Endocyte Inc. (West Lafayette, Ind.; ECYT)3 |
8/17/10 |
2/7 |
14.375 |
$6 |
29.575 |
RBC Capital Markets Leerink Swann (Co-lead) Wedbush PacGrow Life Robert W. Baird |
$86.25 |
$177.45 |
Fluidigm Corp. (South San Francisco; FLDM)4 |
12/3/10 |
2/10 |
6.4S |
$13.50 |
19.8 |
Deutsche Bank Sec. Piper Jaffray (Co-lead) Cowen & Co. Leerink Swann |
$86.4 |
$267.3 |
Pacira Pharmaceuticals Inc. (Parsippany, N.J.; PCRX)5 |
11/1/10 |
2/3 |
6S |
$7 |
17.2 |
Barclays Capital Piper Jaffray (Co-lead) Wedbush PacGrow Life Brean Murray, Carret |
$42 |
$120.4 |
RedHill Biopharma Ltd. (Tel Aviv, Israel; TASE) |
2/8 |
2/8 |
0. 131U |
NIS305 |
N/A |
Poalim IBI Apex Underwriting Issue Management Ltd. Excellence Nessuah Underwriting Meitay Issuing and Fin. Rosario Capital Ltd. |
NIS51.6 ($13.6) |
N/A |
|
Total: $308.5M Number of IPOs in February: 6 Average value of February IPOs: $51 .42M Number of IPOs in 20 1 1: 6 Total raised in IPOs in 20 1 1: $308.5M Average value of IPOs in 20 1 1: $51 .42M | ||||||||
Company (Symbol)# |
Date Filed |
Date Comm. |
Shares/Units (M) |
Price |
Shares Out (M)@ |
Lead, Other Underwriters |
Gross (US$M) |
Post-Offering Market Cap (M)% |
FOLLOW-ON OFFERINGS | ||||||||
Chelsea Therapeutics Inc. (Charlotte, N.C.; CHTP)6 |
1/18 |
2/19 |
10.05S |
$4 |
61.8 |
Deutsche Bank Sec. Ladenburg, Thalmann Wedbush PacGrow Life |
$40.2 |
$247.2 |
Discovery Laboratories Inc. (Warrington, Pa.; DSCO) |
6/11 |
2/17 |
10U |
$2.35 |
23.3 |
Lazard Capital Markets Boenning & Scattergood Global Hunter Sec. |
$23.5 |
$54.8 |
Marina Biotech Inc. (Bothell, Wash.; MRNA) |
9/30 |
2/10 |
6.37U |
$0.80 |
35.4 |
Roth Capital Partners |
$5.1 |
$28.32 |
Opexa Therapeutics Inc. (The Woodlands, Texas; OPXA) |
11/23 2009 |
2/8 |
4.1U |
$2.05 |
23 |
Lazard Capital Markets |
$8.5 |
$47.15 |
Optimer Pharmaceuticals Inc. (San Diego; OPTR)7 |
12/24 2009 |
2/11 |
6S |
$11.25 |
45.3 |
Jefferies Baird Canaccord Genuity JMP Securities Needham & Co. ThinkEquity LLC |
$67.5 |
$509.6 |
Paladin Labs Inc. (Montreal; TSX:PLB) |
2/24 |
2/24 |
1.15S |
C$35 |
N/A |
GMP Securities L.P. Paradigm Capital Inc.RBC Dominion Sec. TD Securities Inc. Versant Partners Inc. Cormark Securities Desjardins Securities |
C$40.25 ($41) |
N/A |
Palatin Technologies Inc. (Cranbury, N.J.; AMEX:PTN) |
2/24 |
2/24 |
23U |
$1 |
34.9 |
Roth Capital Partners Madison Williams & Co. |
$23 |
$34.9 |
Repros Therapeutics Inc. (The Woodlands, Texas; RPRX)10 |
2/1 |
2/7 |
0.69U |
$17.15 |
11 .3 |
Thalmann & Co. Inc. |
$11.8 |
$48.5 |
Savient Pharmaceuticals Inc. (East Brunswick, N.J.; SVNT)8 |
1/31 |
2/1 |
Convertible senior notes |
N/A |
N/A |
J.P. Morgan Securities Lazard Capital Markets Cowen and Co. |
$230 |
N/A |
Seattle Genetics Inc. (Bothell, Wash.; SGEN)9 |
5/09 |
2/2 |
11.5S |
$15.50 |
112.8 |
Jefferies & Co. Inc. J.P. Morgan Sec. (Co-lead) Leerink Swann RBC Capital Markets Needham & Co. William Blair & Co. Oppenheimer & Co. ThinkEquity LLC |
$178.25 |
$1.7B |
Vermillion Inc. (Austin, Texas; VRML)11 |
2/15 |
2/15 |
4S |
$5.45 |
14.4 |
Roth Capital Partners |
$21.8 |
$78.48 |
Ziopharm Oncology Inc. (New York; ZIOP)12 |
5/10/10 |
2/7 |
11 .04S |
$5.75 |
65.64 |
Barclays Capital |
$63.48 |
$377.43 |
OVERALLOTMENT OPTIONS |
||||||||
Ardea Biosciences Inc. (San Diego; RDEA)13 |
11/15 |
2/24 |
0.4125S |
$26 |
26.5 |
BofA Merrill Lynch Jefferies (co-lead) JMP Securities Brean, Murray, Carret Roth Capital Partners |
$10.725 |
$689 |
|
Total: $724.855M Number of follow-on offerings in February: 12 Average value of February follow-ons: $60.4M Number of follow-on offerings in 2011: 20 Total raised in follow-ons in 2011: $1,425.815M Average value of follow-ons in 2011: $71.29M | ||||||||
|
Notes: # Unless otherwise indicated, shares are traded on the Nasdaq exchange. AMEX = American Stock Exchange; TASE = Tel Aviv Stock Exchange; TSX = Toronto Stock Exchange. @ This column reflects the shares outstanding following the offering, when disclosed. % Market capitalization is calculated based on the offering price. Currency conversions are based on exchange rates at the time of the deal. 1 AcelRx's overallotment option: 1.2M shares. 2 Includes BG Medicine's overallotment option: 750,000 shares. 3 Includes Endocyte's overallotment option: 1.875M shares. 4 Includes Fluidigm's overallotment option: 833.750 shares. 5 Pacira's overallotment option: 900,000 shares. 6 Includes Chelsea's overallotment option: 1.3M shares. 7 Optimer's overallotment option: 900,000 shares. 8 Savient raised $200M by offering 4.75% convertible senior notes due 2018, plus an overallotment for another $30M in notes. 9 Includes Seattle Genetics' overallotment option: 1.5M shares. 10 Repros' overallotment option: 90,000 units. Each unit consists of four shares of common stock, three Series A Warrants and 2.45 Series B Warrants. 11 Vermillion's overallotment option: 500,000 shares from the company and 100,000 from a shareholder. 12 Includes Ziopharm's overallotment option: 1.44M shares. 13 Ardea raised an additional $10.725M with its overallotment option, bringing the total raised to $82.225M. | ||||||||
II. FILED AND PENDING | ||||||
Company (Symbol)# |
Date Filed |
Shares/Units (M) |
Price |
Shares Out |
Lead, Other Underwriters (M)@ |
Gross (US$M) |
INITIAL OFFERINGS | ||||||
| Aldagen Inc. (ALDH) |
10/29/09 |
Units |
N/A |
N/A |
Boenning & Scattergood Ladenburg Thalmann (co-lead) National Securities Corp. |
$46 |
| Ambit Biosciences Corp. (AMBT) |
11/5/10 |
N/A |
N/A |
N/A |
J.P. Morgan Credit Suisse (co-lead) Leerink Swann Wedbush PacGrow Life Sci. |
$86.25 |
| BioLineRx Ltd. (BLRX) |
9/24/10 |
N/A |
N/A |
N/A |
JMP Securities Oppenheimer & Co. |
$40.25 |
| Clarus Therapeutics Inc. (Northbrook, Ill.; CLRS) |
11/19/10 (Postponed 2/16) |
5S |
$11-$13 |
18.1 |
Piper Jaffray Wells Fargo (Co-lead) Lazard Capital Markets Needham & Co. |
$60 |
| Cutanea Life Sciences Inc. (CTNA)1 |
11/5/10 |
2.3S |
$6.50 |
3.9 |
Brean Murray, Carret & Co. Rodman & Renshaw LLC (co-lead) |
$14.95 |
| Horizon Pharma Inc. (HZNP) |
8/3/10 |
N/A |
N/A |
N/A |
Jefferies & Co. Piper Jaffray (co-lead) JMP Securities Lazard Capital Markets |
$86.25 |
| Med BioGene Inc.2 (Canada; MGBI) |
12/28/09 |
N/A |
N/A |
N/A |
Rodman & Renshaw LLC |
$24 |
| NewLink Genetics Corp. (NLNK) |
12/21/10 |
N/A |
N/A |
N/A |
Wells Fargo Cowen & Co. (co-lead) Robert W. Baird Canaccord Genuity Needham & Co. LLC |
$86.25 |
| Prometheus RxDx Corp. (RXDX) |
12/19/07 |
N/A |
N/A |
N/A |
Goldman Sachs & Co. Credit Suisse (co-lead) SunTrust Robinson Humphrey Cowen & Co. WedBush PacGrow Life Sci. |
$151.3 |
| Quark Pharmaceuticals Inc. (TASE) |
9/28/10 |
N/A |
N/A |
N/A |
N/A |
$20 |
| Sagent Pharmaceuticals Inc. (SGNT) |
12/7/10 |
N/A |
N/A |
N/A |
Morgan Stanley BofA Merrill Lynch (co-lead) Jefferies & Co. (co-lead) Needham & Co. RBC Capital Markets |
$100 |
| Supernus Pharmaceuticals Inc. (SUPN) |
12/23/10 |
N/A |
N/A |
N/A |
Citibank Barclays Capital (co-lead) Cowen and Co. Stifel Nicolaus Weisel |
$100 |
| Theratechnol-ogies Inc. (Montreal; THER)3 |
2/22/11 |
11S |
$5.08 |
71.5 |
Jefferies & Co. Stifel Nicolaus Weisel (co-lead) RBC Capital Markets (co-lead) BMO Capital Markets (co-lead) Desjardins Securities International NBF Securities (USA) Corp |
$55.88 |
| Tranzyme Pharma Inc. (TZYM) |
11/19/10 |
N/A |
N/A |
N/A |
Citigroup Global Markets BMO Capital Markets Canaccord Genuity Stifel Nicolaus Weisel |
$75 |
| Notes: # Unless otherwise indicated, shares are traded on the Nasdaq exchange. CDNX = Canadian Venture Exchange; TASE = Tel Aviv Stock Exchange. General shelf registration statements are not included until action is taken on the filing. * Stock symbols for companies seeking to complete IPOs are proposed. @ This column reflects the shares outstanding following the offering, when disclosed. N/A = Not available, applicable or reported. The value of all offerings is based on either the midpoint of the price range listed in the company's SEC filing or the most recent closing stock price before the offering was announced. In some cases, the company has not disclosed the number of shares to be offered or a price range. Then, the value is the maximum aggregate offering price listed in the SEC filing. 1 Cutanea's overallotment option: 345,000 shares. 2 Med BioGene is already listed on the Canadian Venture Exchange, ticker symbol "MBI." 3 Theratechnologies is already listed on the Toronto Stock Exchange, ticker symbol "TH." | ||||||